ADVFN US – Market Content Editor
-

American Bitcoin stock surges after adding 1,414 Bitcoin to holdings
American Bitcoin Corp. (NASDAQ:ABTC) shares rose 5.7% in premarket trading Monday after the company announced it had acquired approximately 1,414 Bitcoin, bringing its total Bitcoin holdings to 3,865 as of October 24, 2025. The Bitcoin accumulation platform—which focuses on building U.S. Bitcoin infrastructure—said its total holdings include coins from both mining operations and strategic purchases.…
-

Cellectar Biosciences stock jumps after FDA grants Rare Pediatric Disease Designation
Cellectar Biosciences (NASDAQ:CLRB) shares soared 27% after the company received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for its iopofosine I 131 therapy targeting relapsed or refractory pediatric high-grade glioma. The designation highlights the potential of Cellectar’s radioconjugate monotherapy to address an aggressive and often fatal cancer affecting children and…
-

Red Cat stock surges after breakthrough GPS-denied drone flight tests
Red Cat Holdings Inc (NASDAQ:RCAT) shares jumped 8.3% in premarket trading on Monday after the company announced it had successfully completed flight tests of its Black Widow drone equipped with Palantir Technologies (NYSE:PLTR) Visual Navigation Software. The tests showed that the Black Widow drone—part of the U.S. Army’s Short Range Reconnaissance program—can operate effectively in…
-

Perpetua Resources stock jumps after $255 million equity investment
Perpetua Resources Corp (NASDAQ:PPTA) shares climbed 4.3% in premarket trading Monday after the company announced it had secured $255 million in new equity investments from Agnico Eagle Mines Limited and JPMorgan Chase & Co. The investment comes shortly after Perpetua began construction on its Stibnite Gold Project in central Idaho. Under the agreement, Agnico Eagle—the…
-

Sotherly Hotels stock skyrockets after $2.25 per share buyout announcement
Sotherly Hotels Inc (NASDAQ:SOHO) shares soared 133.4% in premarket trading on Monday after the company revealed it had entered into a definitive merger agreement to be acquired by a joint venture led by Kemmons Wilson Hospitality Partners. Under the agreement, the joint venture will purchase all outstanding shares of Sotherly’s common stock for $2.25 per…
-

Janus Henderson stock jumps after report of Trian Fund buyout bid
Janus Henderson Group (NYSE:JHG) shares surged 13% on Monday after Bloomberg reported that activist investor Nelson Peltz’s Trian Fund Management is preparing a takeover offer for the asset manager. According to the report, Trian is working with General Catalyst on a proposal to purchase the remaining shares of Janus Henderson that it doesn’t already own.…
-

iRobot stock drops after revealing sharply lower takeover offer
iRobot Corporation (NASDAQ:IRBT) shares tumbled 8% on Monday after the company disclosed in an SEC filing that its last remaining potential buyer had made a takeover offer “significantly lower” than its recent trading levels, casting serious doubt on the likelihood of a successful sale. The filing revealed that the company’s strategic review is still ongoing…
-

Lululemon stock gains after announcing NFL merchandise partnership with Fanatics
Lululemon Athletica Inc. (NASDAQ:LULU) shares climbed 2.5% on Monday after a Bloomberg report revealed that the athletic apparel brand has entered a partnership with the National Football League and Fanatics Inc. to launch NFL team-branded merchandise. The collaboration marks Lululemon’s first-ever venture with the NFL and will cover all 32 teams in the league. The…
-

Intellia stock plunges after halting gene therapy trials over safety issue
Intellia Therapeutics (NASDAQ:NTLA) shares plummeted 50% on Monday after the company announced a temporary halt to patient dosing and screening in its Phase 3 trials of nex-z, citing a serious liver-related safety incident. Shares of CRISPR Therapeutics (NASDAQ:CRSP) also slid 10% following the news. The biotech company paused its MAGNITUDE and MAGNITUDE-2 studies, which target…
-

Zenas BioPharma stock skyrockets after strong MS drug trial data
Zenas BioPharma (NASDAQ:ZBIO) shares surged 80% on Monday following the release of highly encouraging Phase 2 results from its MoonStone clinical trial evaluating obexelimab in patients with Relapsing Multiple Sclerosis (RMS). The company said the investigational therapy achieved its primary endpoint, delivering a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo. The…